Possible Involvement of Host Defense Mechanism in the Suppression of Rat Acute Reflux Esophagitis by the Particular Histamine H2 Receptor Antagonist Lafutidine

Nakano, Masaya; Ajioka, Hirofusa; Abe, Masaaki; Kiniwa, Mamoru

doi:10.1159/000342386

Cited by 7 publications

(1 citation statement)

References 26 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It suppresses both daytime and nighttime acid secretion through reversible H 2 receptor antagonism and can provide effective symptom relief in gastroesophageal reflux disease at single daily doses. [6] It has additional mucoprotective effect that is independent of its acid antisecretory activity. A recent study has reported that improved mucosal host-defense via capsaicin-sensitive afferent nerves may contribute to the therapeutic action of lafutidine.…”

Section: Introductionmentioning

confidence: 99%

Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia

et al. 2014

View full text Add to dashboard Cite

Objectives:Lafutidine is a new H2-blocker in India claimed to be more potent and effective than existing H2-blockers. Proton pump inhibitors (PPIs), by virtue of their mechanism of action, have greater efficacy than H2-blockers in gastric acid suppression. However, clinical trials comparing H2-blockers directly with PPIs are limited. We carried out a head-to-head comparison of the effectiveness of lafutidine versus the PPI pantoprazole in uninvestigated dyspepsia [CTRI/2013/12/004261].Materials and Methods:A prospective, open label, randomized, controlled trial was conducted in a tertiary care hospital. Ambulatory adult patients with dyspepsia, not yet subjected to endoscopy, were recruited if they had at least moderately severe symptoms, defined as a score of ≥ 4 on a 7-point Global Overall Symptom (GOS) Scale. Those with alarm features or significant comorbidity were excluded. Subjects received either once daily lafutidine 10 mg or pantoprazole 40 mg, orally, for 8 weeks. Reflux, dysmotility and pain scores were assessed by Modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (mFSSGERD), and quality of life (QoL) by SF-8 scale. The latter had physical and mental components summarized by physical component summary score (PCS) and a mental component summary score (MCS).Results:Of 122 patients enrolled, data of 57 on lafutidine and 60 on pantoprazole were analyzed. At 4 weeks, proportion of subjects responding (GOS score ≤ 2) in the two arms (lafutidine 45.61% vs. pantoprazole 48.33%, P = 0.854) or showing symptom resolution (GOS score ≤ 1) (lafutidine 12.28% vs. pantoprazole 5.00%; P = 0.197) were comparable. Similarly at 8 weeks, both responder (lafutidine 52.63% vs. pantoprazole 56.67%; P = 0.712) and symptom resolution proportions (lafutidine 33.33% vs. pantoprazole 30%; P = 0.843) were comparable. Total score on mFSSGERD scale, as well as all its three component scores, and PCS and MCS scores on QoL SF-8 scale showed improvement but no statistically significant difference between the two arms. Tolerability of both drugs was excellent.Conclusions:Lafutidine is well-tolerated and there is no clinically worthwhile difference between the two drugs in the empirical treatment of uninvestigated dyspepsia.

show abstract

Section: Introductionmentioning

confidence: 99%

Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia

et al. 2014

View full text Add to dashboard Cite

show abstract

Critical Evaluation of Animal Models of Gastrointestinal Disorders

Johnson

Meerveld

2017

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Preclinical research remains an important tool for discovery and validation of novel therapeutics for gastrointestinal disorders. While in vitro assays can be used to verify receptor-ligand interactions and test for structural activity of new compounds, only whole-animal studies can demonstrate drug efficacy within the gastrointestinal system. Most major gastrointestinal disorders have been modeled in animals; however the translational relevance of each model is not equal. The purpose of this chapter is to provide a critical evaluation of common animal models that are being used to develop pharmaceuticals for gastrointestinal disorders. For brevity, the models are presented for upper gastrointestinal disorders involving the esophagus, stomach, and small intestine and lower gastrointestinal disorders that focus on the colon. Particular emphasis is used to explain the face and construct validity of each model, and the limitations of each model, including data interpretation, are highlighted. This chapter does not evaluate models that rely on surgical or other non-pharmacological interventions for treatment.

show abstract

Morphologic characteristics of esophageal epithelium in a rat model of duodenoesophageal reflux and protective effect of lafutidine

et al. 2014

View full text Add to dashboard Cite

Possible Involvement of Host Defense Mechanism in the Suppression of Rat Acute Reflux Esophagitis by the Particular Histamine H2 Receptor Antagonist Lafutidine

Cited by 7 publications

References 26 publications

Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia

Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia

Critical Evaluation of Animal Models of Gastrointestinal Disorders

Morphologic characteristics of esophageal epithelium in a rat model of duodenoesophageal reflux and protective effect of lafutidine

Contact Info

Product

Resources

About